Javascript must be enabled to continue!
Generation of a Synthetic Single Domain Antibody Library for Radiopharmaceutical Ligand Discovery
View through CrossRef
ABSTRACTSingle domain antibodies, often known as nanobodies, are versatile molecules with therapeutic and diagnostic applications, but they are primarily developed through immunization of camelids. This approach is not scalable by automation, not effective for non-immunogenic or toxic antigens, and prevents the use of modified scaffolds for altered pharmacokinetic properties. Synthetic libraries allow for pre-selection of a single domain framework tailored to its intended downstream use. One area of interest for these biologic vectors is radiopharmaceuticals. Ideal radiopharmaceutical pharmacokinetic properties differ from most traditional therapeutics, as short plasma circulation and rapid kidney clearance are necessary to avoid dose-limiting organ radiation. Although there are a growing number of nanobody radiopharmaceuticals in clinical trials, their frameworks and corresponding pharmacokinetic properties vary. One potential method for improving the development of novel single domain antibody radiopharmaceuticals is through synthetic libraries based on nanobodies with proven clinically acceptable pharmacokinetics. We developed a modular synthetic nanobody phage display vector based on the scaffold of the 2Rs15d nanobody that allows for manipulation of the binding and framework regions. Using this vector, we created a library of nanobodies with a randomized CDR2 containing over 1.7×106unique sequences/µL. As a proof-of-concept, we panned the library for nanobodies binding calreticulin (CALR), a protein critical in immunogenic cell death. One isolated clone, Cal3, has a measured affinity of 140 nM for CALR and is cross-reactive with mouse and human CALR. Using positron emission tomography (PET) imaging, the radiolabeled64Cu-NOTA-Cal3 demonstrated CALR bindingin vivo, representing the first reported synthetic nanobody characterized by PET imaging. This study demonstrates the feasibility of building and panning synthetic libraries for high-affinity radiopharmaceutical nanobodies as an alternative to immunized camelid libraries.
Cold Spring Harbor Laboratory
Title: Generation of a Synthetic Single Domain Antibody Library for Radiopharmaceutical Ligand Discovery
Description:
ABSTRACTSingle domain antibodies, often known as nanobodies, are versatile molecules with therapeutic and diagnostic applications, but they are primarily developed through immunization of camelids.
This approach is not scalable by automation, not effective for non-immunogenic or toxic antigens, and prevents the use of modified scaffolds for altered pharmacokinetic properties.
Synthetic libraries allow for pre-selection of a single domain framework tailored to its intended downstream use.
One area of interest for these biologic vectors is radiopharmaceuticals.
Ideal radiopharmaceutical pharmacokinetic properties differ from most traditional therapeutics, as short plasma circulation and rapid kidney clearance are necessary to avoid dose-limiting organ radiation.
Although there are a growing number of nanobody radiopharmaceuticals in clinical trials, their frameworks and corresponding pharmacokinetic properties vary.
One potential method for improving the development of novel single domain antibody radiopharmaceuticals is through synthetic libraries based on nanobodies with proven clinically acceptable pharmacokinetics.
We developed a modular synthetic nanobody phage display vector based on the scaffold of the 2Rs15d nanobody that allows for manipulation of the binding and framework regions.
Using this vector, we created a library of nanobodies with a randomized CDR2 containing over 1.
7×106unique sequences/µL.
As a proof-of-concept, we panned the library for nanobodies binding calreticulin (CALR), a protein critical in immunogenic cell death.
One isolated clone, Cal3, has a measured affinity of 140 nM for CALR and is cross-reactive with mouse and human CALR.
Using positron emission tomography (PET) imaging, the radiolabeled64Cu-NOTA-Cal3 demonstrated CALR bindingin vivo, representing the first reported synthetic nanobody characterized by PET imaging.
This study demonstrates the feasibility of building and panning synthetic libraries for high-affinity radiopharmaceutical nanobodies as an alternative to immunized camelid libraries.
Related Results
Radiopharmaceutical Therapy
Radiopharmaceutical Therapy
Abstract
Radiopharmaceutical therapy involves the use of radionuclides that are either conjugated to tumor-targeting agents (e.g., nanoscale constructs, antibodies, pepti...
Procedure for Western blot v1
Procedure for Western blot v1
Goal: This document has the objective of standardizing the protocol for Western blot. This technique allows the detection of specific proteins separated on polyacrylamide gel and t...
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
IgM antibody to hepatitis C virus in acute and chronic hepatitis C
To assess possible role of testing for IgM-specific antibody in the diagnosis and monitoring of patients with hepatitis C, we tested sera from 14 patients with acute and 97 patient...
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
MARS-seq2.0: an experimental and analytical pipeline for indexed sorting combined with single-cell RNA sequencing v1
Human tissues comprise trillions of cells that populate a complex space of molecular phenotypes and functions and that vary in abundance by 4–9 orders of magnitude. Relying solely ...
Abstract 5051: RenMab Mouse: A leading platform for fully human antibody generation
Abstract 5051: RenMab Mouse: A leading platform for fully human antibody generation
Abstract
With the development of immune-oncology, therapeutic antibodies have been proven to be extraordinarily effective for cancer treatment. Conventional human an...
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer
Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer
AbstractTheranostics – i.e., the combination of molecular imaging and radiopharmaceutical therapy of cancer targeting a common biological feature – is a rapidly expanding field owi...
Mesoscale Modeling of a Nucleosome-Binding Antibody (PL2-6): Mono- vs. Bivalent Chromatin Complexes
Mesoscale Modeling of a Nucleosome-Binding Antibody (PL2-6): Mono- vs. Bivalent Chromatin Complexes
ABSTRACTVisualizing chromatin adjacent to the nuclear envelope (denoted “epichromatin”) by in vitro immunostaining with a bivalent nucleosome-binding antibody (termed monoclonal an...
Retrospective analysis of the clinical significance of Ro52/TRIM21 antibody and specific antinuclear antibody patterns by indirect immunofluorescence
Retrospective analysis of the clinical significance of Ro52/TRIM21 antibody and specific antinuclear antibody patterns by indirect immunofluorescence
Objectives: To determine the clinical significance of Ro52 protein/tripartite motif-containing 21 antibody and specific antinuclear antibody patterns using indirect immunofluoresce...

